re: re 14c s'term target.why the fall then >
Mightybull, I'm not game to speculate on potential price but it's safe to say that days of 4c are gone and pretty soon I think it'll be the same said for 10c. Just the usual retrace going on with heavy day-trading. But I do agree with one thing, the potential for this company is huge.
Commercialisation Agreements in India/sub continent: SciGen has insulin commercialization agreements in place for the major markets in the Indian Sub-Continent (India, Pakistan, Bangladesh and Sri Lanka). (agreements in place with Ranbaxy, India’s largest pharmaceutical company and a global giant in generic drugs, and Shreya Life Sciences for marketing and sales of SciLin in India). Note that Shreya also have operations in Russia. commercialisation agreement with Zafa Pharmaceutical for the marketing, sale and distribution of SciGen’s human insulin throughout Pakistan.The agreement is on a non-exclusive basis for 10 years which allows SciGen to engage other distribution partners in Pakistan if it so wishes.
Non-Exclusive Commercialisation agreement with China
Manufacturing Plant in Middle East: Has a manufacturing plant (hepB vaccine) in Israel and production of first batches expected any day.
Entry into European Markets: Bioton a leading biotek from Poland had previously acquired a 24% stake, and in Oct 05 increased this by acquiring a further 18.6% in SIE shares. And has exclusive distributor (Berna) for Sci-B-Vac TM in Western Europe.
It goes on and on
Product Registrations in SE Asia (Philipines, Thailand, Singapore, Hong Kong, Vietnam
Further product development through alliance with Austrian based biotek Intercell.
Cheers, Pol
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Held
